Abstracts Archive - Page 1895 of 2607 - ACR Meeting Abstracts

Abstract Number: 356 • 2015 ACR/ARHP Annual Meeting
Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Keisuke Hagihara⁴, Hideki Yoshikawa⁵ and Takaaki Noguchi⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Kampo Medicine, Osaka University, Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ⁶Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan
Background/Purpose: In patients with rheumatic diseases (RD), pro-inflammatory cytokines induce receptor activator of nuclear factor kappa-B ligand (RANKL), which plays a crucial role in inducing…
Abstract Number: 357 • 2015 ACR/ARHP Annual Meeting
Human Parathyroid Hormone for Preventing and Treating Glucocorticoid-Induced Osteoporosis: Cochrane Systematic Review and Meta-Analysis
Akira Onishi¹, Akira Sato², Masahiro Iwasaku² and Toshi Furukawa², ¹Department for Rheumatology, Kobe University Hospital, Kobe, Japan, ²Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan
Background/Purpose: Although glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis, providing effective treatment remains a challenge. Bisphosphonates are currently recommended for treatment and…
Abstract Number: 358 • 2015 ACR/ARHP Annual Meeting
Bone Microstructure Assessed By Hrpqct in Subjects with Hyperuricemia without Arthritis
Roland Kocijan¹, Arastoo Nia¹, Christian Muschitz², David Simon³, Corinna Geiger¹, Judith Haschka⁴, Arnd Kleyer³, Sara Bayat⁵, Juergen Rech⁵, Annemarie Kocijan⁶, Larissa Dzirlo⁷, Monika Graninger⁷ and Heinrich Resch¹, ¹Medical Department II, Karl Landsteiner Society for Gastroenterology and Rheumatology, St. Vincent Hospital, Vienna, Austria, ²Medical Department II, St. Vincent Hospital, Vienna, Austria, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Optimal Essen e.U., Vienna, Austria, ⁷Medical Department III, St. Vincent Hospital, Vienna, Austria
Background/Purpose: Gouty arthritis is a common inflammatory joint disorder and hyperuricemia (HU) is known to be the main risk factor. Beside clinical signs of inflammation…
Abstract Number: 359 • 2015 ACR/ARHP Annual Meeting
Diminished Health-Related Quality of Life As Measured By the Short Form-10 in Children with Hypophosphatasia
Thomas J. Weber¹, Eileen K. Sawyer², Scott Moseley² and Priya S. Kishnani¹, ¹Duke University Medical Center, Durham, NC, ²Alexion Pharmaceuticals, Cheshire, CT
Background/Purpose: Hypophosphatasia is a rare metabolic disease caused by loss-of-function mutation(s) in the gene encoding the tissue non-specific alkaline phosphatase (ALP). In children, low tissue…
Abstract Number: 360 • 2015 ACR/ARHP Annual Meeting
Massive Elimination of Multinucleated Osteoclasts By Eupatilin Is Due to Dual Inhibition of Transcription and Cytoskeletal Rearrangement
Myeung Su Lee¹, Ju-Young Kim², Chang-Hoon Lee³, Wan-Hee Yoo⁴, Won Seok Lee⁴, Myong-Joo Hong⁵ and Jaemin Oh², ¹Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ²Anatomy, Wonkwang University, Iksan, South Korea, ³Rheumatology, Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, ⁴Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁵Internal Medicine, Presbyterian Medical center, Jeonju, South Korea
Background/Purpose: Osteoporosis is an ageing-associated diseases requiring better therapeutic modality. Eupatilin is a major flavonoid from Artemisia. We aimed to evaluate the effects of eupatilin on…
Abstract Number: 361 • 2015 ACR/ARHP Annual Meeting
Sodium Intake and Osteoporosis. Findings from the Women’s Health Initiative
Laura Carbone¹, Karen Johnson², Ying Huang³, Mary Pettinger⁴, Thomas Fridtjof⁵, Jane A. Cauley⁶, Carolyn Crandall⁷, Lesley Tinker⁸, Meryl LeBoff⁹, Jean Wactawksi-Wende¹⁰, Monique Bethel¹¹, Wenjun Li¹² and Ross Prentice³, ¹Rheumatology, Georgia Regents University, Augusta, GA, ²Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, ³Biostatistics, University of Washington, Seattle, WA, ⁴Fred Hutcinson Cancer Research Center, Seattle, WA, ⁵University of Tennessee Health Science Center, Memphis, TN, ⁶Department of Epidemiology, Univ of Pittsburgh, Pittsburgh, PA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Buffalo, Buffalo, NY, ¹¹Internal Medicine, Georgia Regents University, Augusta, GA, ¹²Medicine, Division of Preventive Medicine, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The relationship of sodium intake to bone mineral density (BMD) in postmenopausal women has not been established, and no study to date has examined…
Abstract Number: 362 • 2015 ACR/ARHP Annual Meeting
Reference Curves of Bone Parameters Obtained By High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) in Healthy Women from 20 to 85 Years Old
Jackeline Couto Alvarenga¹, Henrique Fuller², Sandra G. Pasoto², Stephanie Boutroy³ and Rosa M R Pereira⁴, ¹Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³INSERM U831 and Université de Lyon, Lyon, France, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Bone is a dynamic tissue, and its formation and resorption are continuous processes that promote changes throughout the life of the organism, and changes…
Abstract Number: 363 • 2015 ACR/ARHP Annual Meeting
Determination of the Osteoporotic Vertebral Fractures By a New Quantitative Approach: Intervertebral Volume Index
Omer Kuru¹, Yasemin Ulus², Halil Sen², Bunyamin Sahin³ and Ayhan Bilgici², ¹Physical Medicine And Rehabilitation Division of Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, ²Physical Medicine and Rehabilitation Division of Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, ³Anatomy, Ondokuz Mayis University School of Medicine, Samsun, Turkey
Background/Purpose: Vertebral fractures caused by osteoporosis are quite common and have a negative effect on quality of the life. But they may not be clinically…
Abstract Number: 364 • 2015 ACR/ARHP Annual Meeting
Very High Frequency of Fragility Fractures Associated with High-Dose Glucocorticoids in Postmenopausal Women: A Retrospective Study
Goichi Kageyama¹, Takaichi Okano¹, Yuzuru Yamamoto¹, Keisuke Nishimura¹, Daisuke Sugiyama², Jun Saegusa¹, Goh Tsuji³, Shunichi Kumagai⁴ and Akio Morinobu¹, ¹Department of Rheumatology, Kobe University Hospital, Kobe, Japan, ²Department of Preventive Medicine and Public Health, Keio University, Tokyo, Japan, ³The Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴The Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: To evaluate the incidence of fragility fractures associated with high-dose glucocorticoid therapy in patients with systemic rheumatic disease.Methods: A retrospective study of patients who were treated with high-dose…
Abstract Number: 365 • 2015 ACR/ARHP Annual Meeting
Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials
JP Brown¹, P Dakin², P Hadji³, MR McClung⁴, PD Miller⁵, J-Y Reginster⁶, RB Wagman², A Wang² and E McCloskey⁷, ¹Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Philipps-University of Marburg, Marburg, Germany, ⁴Oregon Osteoporosis Center, Portland, OR, ⁵Colorado Center for Bone Research, Lakewood, CO, ⁶University of Liège, Liège, Belgium, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Bone turnover markers (BTMs) respond faster than bone mineral density as an indicator of response to therapy in osteoporotic patients; however, it remains unclear…
Abstract Number: 366 • 2015 ACR/ARHP Annual Meeting
Cost-Effective Osteoporosis Treatment Intervention Thresholds Based on FRAX in Portugal
Andréa Marques¹, Oscar Lourenço², Ortsäter Gustaf³, Fredrik Borgström³ and Jose Da Silva⁴, ¹Rheumatology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ²Centro de Estudos e Investigação em Saúde da Universidade de Coimbra, Faculty of Economics. University of Coimbra, Coimbra, Portugal, ³Quantify Research, Stockholm, Sweden, ⁴Faculty of Medicine. University of Coimbra, Coimbra, Portugal
Background/Purpose: The aim of the present study was to identify the FRAX®Port (FRAX® validated for Portugal) ten-year major and hip osteoporotic fracture probabilities, above which…
Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 368 • 2015 ACR/ARHP Annual Meeting
The Effects of Monitoring on a Quality Indicator for Glucocorticoid–Induced Osteoporosis and Trends of the Drug Variation in a Japanese Hospital
Masei Suda¹, Masato Okada¹, Yasuhiro Suyama², Mitsumasa Kishimoto¹ and Tokutaro Tsuda¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Rheumatology, JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most clinically significant side effects of glucocorticoid use, and the prevention of GIOP has become more important…
Abstract Number: 369 • 2015 ACR/ARHP Annual Meeting
Incidence of Fragility Hip Fractures over 10 Years (2004-13) in Three UK Centres with Reference to Local Fracture Prevention (‘fracture liaison’) Service Activity
Gavin Clunie¹ and Jonathan Belsey², ¹Rheumatology, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom, ²JB Medical, Sudbury, United Kingdom
Background/Purpose: Fracture Liaison Services systematically identify patients with fragility fracture and screen patients for osteoporosis and associated conditions and instigate evidence-based 'secondary' fracture prevention management.…
Abstract Number: 370 • 2015 ACR/ARHP Annual Meeting
Impact of Didactic Lecture on Osteoporosis Screening and Fracture Risk Assessment Among House Staff
Meghan Greenfield¹, Jordan Brodsky² and Erin Patton³, ¹Rheumatology, University Of Washington, Seattle, WA, ²Medicine, Albert Einstein College of Medicine, Bronx, NY, ³Medicine/Rheumatology, Mount Sinai Beth Israel, New York, NY
Background/Purpose: It has been estimated that 12 million Americans over the age of 50 have osteoporosis. Of those, only 30% of eligible women age 65…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].